Porcelli L - Search Results

1

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function.

Van Der Steen N, Keller K, Dekker H, Porcelli L, Honeywell RJ, Van Meerloo J, Musters RJP, Kathmann I, Frampton AE, Liu DSK, Ruijtenbeek R, Rolfo C, Pauwels P, Giovannetti E, Peters GJ. Van Der Steen N, et al. Among authors: porcelli l. J Cell Physiol. 2020 Nov;235(11):8085-8097. doi: 10.1002/jcp.29463. Epub 2020 Jan 20. J Cell Physiol. 2020. PMID: 31960422 Free PMC article.

2

Intracellular trafficking of MDR transporters and relevance of SNPs.

Porcelli L, Lemos C, Peters GJ, Paradiso A, Azzariti A. Porcelli L, et al. Curr Top Med Chem. 2009;9(2):197-208. doi: 10.2174/156802609787521562. Curr Top Med Chem. 2009. PMID: 19200005 Review.

3

The impact of folate status on the efficacy of colorectal cancer treatment.

Porcelli L, Assaraf YG, Azzariti A, Paradiso A, Jansen G, Peters GJ. Porcelli L, et al. Curr Drug Metab. 2011 Dec;12(10):975-84. doi: 10.2174/138920011798062274. Curr Drug Metab. 2011. PMID: 21787267 Review.

4

The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.

Porcelli L, Giovannetti E, Assaraf YG, Jansen G, Scheffer GL, Kathman I, Azzariti A, Paradiso A, Peters GJ. Porcelli L, et al. Curr Drug Targets. 2014;15(14):1322-30. doi: 10.2174/1389450116666141205145620. Curr Drug Targets. 2014. PMID: 25479544

5

Small-Cell Lung Cancer: Is Liquid Biopsy a New Tool Able to Predict the Efficacy of Immunotherapy?

Fasano R, Serratì S, Rafaschieri T, Longo V, Di Fonte R, Porcelli L, Azzariti A. Fasano R, et al. Among authors: porcelli l. Biomolecules. 2024 Mar 25;14(4):396. doi: 10.3390/biom14040396. Biomolecules. 2024. PMID: 38672414 Free PMC article. Review.

6

The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).

Azzariti A, Xu JM, Porcelli L, Paradiso A. Azzariti A, et al. Among authors: porcelli l. Biochem Pharmacol. 2004 Jul 1;68(1):135-44. doi: 10.1016/j.bcp.2004.03.014. Biochem Pharmacol. 2004. PMID: 15183125

7

Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects.

Azzariti A, Porcelli L, Xu JM, Simone GM, Paradiso A. Azzariti A, et al. Among authors: porcelli l. World J Gastroenterol. 2006 Aug 28;12(32):5140-7. doi: 10.3748/wjg.v12.i32.5140. World J Gastroenterol. 2006. PMID: 16937523 Free PMC article.

8

Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells.

Sebastian S, Azzariti A, Accardi R, Conti D, Pilato B, LaCalamita R, Porcelli L, Simone GM, Tommasi S, Tommasino M, Paradiso A. Sebastian S, et al. Among authors: porcelli l. Int J Mol Med. 2008 Jun;21(6):809-17. doi: 10.3892/ijmm.21.6.809. Int J Mol Med. 2008. PMID: 18506376

9

EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.

Quatrale AE, Porcelli L, Silvestris N, Colucci G, Angelo A, Azzariti A. Quatrale AE, et al. Among authors: porcelli l. Front Biosci (Landmark Ed). 2011 Jan 1;16(5):1962-72. doi: 10.2741/3833. Front Biosci (Landmark Ed). 2011. PMID: 21196276 Free article. Review.

10

MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.

Azzariti A, Quatrale AE, Porcelli L, Colabufo NA, Cantore M, Cassano G, Gasparre G, Iannelli G, Tommasi S, Panaro MA, Paradiso A. Azzariti A, et al. Among authors: porcelli l. Eur J Pharmacol. 2011 Nov 16;670(1):74-84. doi: 10.1016/j.ejphar.2011.08.025. Epub 2011 Sep 5. Eur J Pharmacol. 2011. PMID: 21925160

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

64 results

Search Page